Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Is Teva Among Finalists In Bidding For Germany's Ratiopharm? (Part 2 of 2)

This article was originally published in The Pink Sheet Daily

Executive Summary

Ratiopharm would bring market share, geographic diversification, and an attractive OTC business - if the price is right.

You may also be interested in...



Teva Wins Ratiopharm For $5 Billion And Gains A Key Foothold In Europe

Teva has emerged as the winner in a months-long bidding war for ratiopharm, Germany's second-largest generics manufacturer after Novartis's Sandoz unit

Teva Wins Ratiopharm For $5 Billion And Gains A Key Foothold In Europe

Teva has emerged as the winner in a months-long bidding war for ratiopharm, Germany's second-largest generics manufacturer after Novartis's Sandoz unit

Teva Wins Ratiopharm For $5 Billion, And Gains A Key Foothold In Europe

The acquisition makes Teva the leading generics company in Europe, which is a key to its ambitious plans for global growth.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS070146

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel